Global Proliferative Diabetic Retinopathy (PDR) Market Report 2024: Market Size, CAGR, Lucrative Segments And Top Regions|Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc.

Overview and Scope
Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management.

Sizing and Forecast
The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Segmentation & Regional Insights
The proliferative diabetic retinopathy (pdr) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
3) By Application: Hospitals; Clinics; Other Applications

North America was the largest region in the proliferative diabetic retinopathy market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Major Driver Impacting Market Growth
The rising prevalence of diabetes is expected to propel the growth of the proliferative diabetic retinopathy (PDR) market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. Diabetes is the leading cause of proliferative diabetic retinopathy disease, which can be treated by various methods that prevent further damage to the retina and preserve vision. For instance, in 2021, according to the International Diabetes Federation (IDF), a Belgium-based organization, 537 million adults aged between 20-79 are suffering from diabetes (1 in 10 people) and this number is expected to reach about 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes drives the proliferative diabetic retinopathy (PDR) market.

Key Industry Players
Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

The proliferative diabetic retinopathy (pdr) market report table of contents includes:

1. Executive Summary
2.Proliferative Diabetic Retinopathy (PDR) Market Characteristics
3.Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies
4.Proliferative Diabetic Retinopathy (PDR) Market analy
5.Proliferative Diabetic Retinopathy (PDR) Market Size And Growth
6.Proliferative Diabetic Retinopathy (PDR) Segmentation
7.Proliferative Diabetic Retinopathy (PDR) Regional And Country Analysis
.
.
.
27.Proliferative Diabetic Retinopathy (PDR) Competitive Landscape And Company Profiles
28.Proliferative Diabetic Retinopathy (PDR) Key Mergers And Acquisitions
29.Proliferative Diabetic Retinopathy (PDR) Future Outlook and Potential Analysis

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model